At 8 h after injection of guanethidine, 1 mg/kg, into the third ventricle of the brain in male rats, plasma corticosterone was 38.8±3.2 µ g/100 ml and hypothalamic norepinephrine (NE) and dopamine (DA) were l.08±0.l0 and 0.27±0.06 µ g/g, respectively. After intraperitoneal injection of guanethidine, 30 mg/kg, plasma corticosterone was 4.7 ± 1.1 and hypothalamic NE and DA were 1.86 ± 0.09 and 0.37 ± 0.08. Since guanethidine does not cross the blood-brain barrier, these observations support the hypothesis that adrenergic inhibition of ACTH secretion is mediated by adrenergic neurons in the central nervous system. Following specific depletion of NE by FLA-63, an inhibitor of dopamine-β-oxidase, plasma corticosterone was 56.4 ± 6.2. Hypothalamic NE content was decreased 50% while DA content was unchanged. This suggests that the adrenergic inhibition is mediated by norepinephrine rather than dopamine.

Keywords:
Corticosterone, Hypothalamus, Norepinephrine, Dopamine, Guanethidine, Dopamine-β-oxidase inhibitor, ACTH
This content is only available via PDF.
© 1972 S. Karger AG, Basel
1972
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.